Understanding the Regulatory Environment Surrounding Pharmaceutical 3DP Technologies
Tom O'Connor - Deputy Office Director, FDA
Ahmed Zidan - Senior Staff Pharmacologist at Center for Drug Evaluation and Research, FDA
Kathi Rinesmith - Senior Vice President of Regulatory Affairs, Aprecia Pharmaceuticals
Mansoor Khan - Regents Professor and Vice Dean, Rangel College of Pharmacy at Texas A&M University - College Station
Blaine Groat - Senior Scientist, US Pharmacopeia
Alton Johnson (Pharmaceutical Consultant, Retired Pfizer Executive)
The educational series will bring together leading 3D-Printing experts from around the globe to discuss exciting technological advancements, applications for pharmaceutical product development, and commercial manufacturing.
Building on the USP and International Association for Pharmaceutical Technology (APV) sponsored four-day event held in July 2020, focused on the Quality of 3D Printing of Medicines and Supplements, this event will explore the use of various 3DP technologies to support new indications, improved formulations, or new delivery systems. The series will provide examples—including case studies for pharmaceutical executives—on how 3DP manufacturing can accelerate clinical development, enhance the innovation value of novel molecules, and extend the life cycle of approved products.